Compounds > omeprazole

omeprazole and imatinib mesylate

omeprazole has been researched along with imatinib mesylate in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Ardau, R; Chillotti, C; De Lisa, R; Del Zompo, M; Severino, G1
Breedveld, P; Cipriani, G; Pluim, D; Schellens, JH; Schinkel, AH; van Tellingen, O; Wielinga, P1
Appleman, LR; Beumer, JH; Christner, SM; Egorin, MJ; Komazec, KA; Miller, BM; Redner, RL; Shah, DD; Yerk, MA1

Trials

1 trial(s) available for omeprazole and imatinib mesylate

ArticleYear
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.
    British journal of clinical pharmacology, 2009, Volume: 68, Issue:3

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzamides; Chromatography; Female; Humans; Imatinib Mesylate; Male; Mass Spectrometry; Omeprazole; Piperazines; Proton Pump Inhibitors; Pyrimidines

2009

Other Studies

4 other study(ies) available for omeprazole and imatinib mesylate

ArticleYear
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
    Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Agents; Benzamides; Drug Eruptions; Edema; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lansoprazole; Middle Aged; Omeprazole; Piperazines; Proton Pump Inhibitors; Pyrimidines; Stevens-Johnson Syndrome

2005
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in pat
    Cancer research, 2005, Apr-01, Volume: 65, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Biological Transport; Brain; Dogs; Drug Synergism; Humans; Imatinib Mesylate; Male; Membranes; Methotrexate; Mice; Mice, Knockout; Neoplasm Proteins; Omeprazole; Pantoprazole; Piperazines; Pyrimidines; Spodoptera; Sulfoxides; Tetrahydroisoquinolines

2005